serum enterolactone prognosis postmenopausal breast cancer pubmed ncbi abstract purpose lignans--plant-derived compounds estrogen-dependent independent anticarcinogenic properties--have postmenopausal breast cancer risk data limited effect survival dietary lignans metabolized enterolignans subsequently absorbed bioavailable patients methods assessed prognosis num postmenopausal patients breast cancer age num num years diagnosed num num vital status end num ascertained local population registries deaths verified death certificates information recurrences secondary tumors verified clinical records attending physicians associations postdiagnostic serum enterolactone biomarker dietary lignans survival distant disease-free survival assessed cox proportional hazards models stratified age diagnosis adjusted prognostic factors results median enterolactone levels deceased patients alive num num nmol/l median num years follow-up diagnosis num deaths confirmed higher serum enterolactone levels significantly reduced hazard ratios hrs death hr num nmol/l increment num num hr highest quartile num num ci num num distant disease hr num num nmol/l increment num num num ci num num highest quartile highest quartile serum enterolactone significantly reduced risk death estrogen receptor-negative tumors hr num num ci num num estrogen receptor-positive tumors hr num num ci num num heterogeneity num conclusion postmenopausal patients breast cancer high serum enterolactone levels survival 
